Evolus, Inc. (NASDAQ:EOLS) Shares Sold by State Street Corp

State Street Corp reduced its holdings in Evolus, Inc. (NASDAQ:EOLS) by 4.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,277,841 shares of the company’s stock after selling 61,236 shares during the period. State Street Corp owned approximately 2.02% of Evolus worth $20,701,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of EOLS. Armistice Capital LLC purchased a new position in Evolus in the 2nd quarter worth approximately $3,906,000. Charles Schwab Investment Management Inc. increased its holdings in shares of Evolus by 173.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 418,576 shares of the company’s stock valued at $6,781,000 after purchasing an additional 265,635 shares during the last quarter. Ikarian Capital LLC purchased a new position in Evolus during the third quarter worth approximately $4,184,000. Walleye Capital LLC acquired a new position in Evolus during the third quarter worth $3,438,000. Finally, Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in Evolus in the 2nd quarter valued at $1,326,000. 90.69% of the stock is currently owned by institutional investors and hedge funds.

Evolus Trading Down 0.5 %

NASDAQ EOLS opened at $10.84 on Tuesday. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23. The stock has a market capitalization of $686.40 million, a P/E ratio of -11.91 and a beta of 1.27. The firm’s 50-day moving average is $13.81 and its two-hundred day moving average is $13.78. Evolus, Inc. has a 12 month low of $9.80 and a 12 month high of $17.82.

Analysts Set New Price Targets

Several research analysts have recently commented on EOLS shares. HC Wainwright reiterated a “buy” rating and set a $27.00 price target on shares of Evolus in a report on Thursday, November 7th. Barclays lifted their target price on shares of Evolus from $16.00 to $20.00 and gave the stock an “overweight” rating in a research note on Friday, September 13th. Cantor Fitzgerald reissued an “overweight” rating on shares of Evolus in a research note on Monday, September 16th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price target on shares of Evolus in a research report on Friday, September 13th.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.